IL12B and infection: Thus, since immune cells exert important role in controlling lung infection, the potential risk of IL12β antibody (such as Ustekinumab) may increase infection, particular lung infection (55), although anti-IL12β antibody has been generally well tolerated by patients in clinical trials, with most adverse events being mild in severity (56, 57).